Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Eiger BioPharmaceuticals Inc EIGR

Healthcare Biotechnology
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.


NDAQ:EIGR - Post by User

Eiger BioPharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by Trader24on Sep 03, 2015 12:40pm
301 Views
Post# 24075688

a

aAugust 31 Deadline in Lawsuit for Investors in Celladon Corp (NASDAQ:CLDN) Shares Announced by Shareholders Foundation 25 Aug 2015 - ACQUIREMEDIA The Shareholders Foundation, Inc. announces that a lawsuit was filed against Celladon Corp over alleged Securities Laws Violations and that a deadline is upcoming on August 31, 2015 for investors with a substantial investment in shares between July 7, 2014 and June 25, 2015. Investors who purchased a significant amount of shares of Celladon Corp between July 7, 2014 and June 25, 2015 and suffered SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Celladon Corporation of Class Action Lawsuit and Upcoming Deadline CLDN 24 Aug 2015 - ACQUIREMEDIA GPM Announces the Filing of a Securities Class Action on Behalf of Celladon Corp. Investors
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities